PNM is a clinical-stage biotechnology company dedicated to developing cutting-edge technologies that target the underlying causes of brain diseases, not just their symptoms. Our focus is on advancing novel methods for the effective delivery of disease-modifying drugs to the brain, aiming to tackle conditions such as brain tumors, epilepsy, stroke, and neurodegenerative diseases. By addressing the primary barrier to effective therapy—achieving adequate drug delivery to the brain—we strive to dramatically improve patient outcomes.
Improved catheter design to optimize drug delivery
and patient safety
AI driven personalized planning customized to patient anatomy and disease
IL13-PE38 for glioblastoma multiforme – targeting the tumor stem cells